Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study.
BACKGROUND
The aim of this study was to confirm the clinical efficacy and safety of a preseasonal sublingual immunotherapy (SLIT) in a group of allergic patients with seasonal rhinoconjunctivitis with or without mild intermittent or mild persistent asthma. The immunotherapy was administered through the oral mucosa with a monomeric carbamylated allergoid (allergoid SLIT) for grass pollens. A secondary endpoint was to evaluate the effect of the allergoid SLIT on nasal reactivity.


RESULTS
A single-center, randomized, double-blind, placebo-controlled study was performed. Patients were selected and randomly allocated to two groups: one group received active treatment (allergoid SLIT) for 2 years and the other received placebo. Both groups received the necessary drug treatment throughout the trial. Thirty-three outpatients (20 men and 13 women, mean age: 30 years; range: 19-43) attending our center were enrolled in the study. Symptoms and medications were scored on diary cards during the pollen season. An allergen nasal challenge was performed at baseline and after 2 years of SLIT to evaluate nasal reactivity. Because the clinical scores were non-normally distributed, the Mann-Whitney and the Chi-square tests for intergroup comparisons and the Wilcoxon test for intragroup comparisons were used. The results were evaluated after 1 and 2 years of treatment. Between the first and second years of treatment, no changes in the scores for the placebo group were found, while for the active vaccine group significant decreases were found in rhinorrhea (p < 0.03), sneezing (p < 0.03), and conjunctivitis (p < 0.02). Symptom scores after nasal challenge decreased (p < 0.03) after 2 years' treatment. Nasal steroid use significantly decreased in the active treatment group during May and June in both the years of treatment (p < 0.02). Only two mild local adverse events were reported in the active group and none was reported in the placebo group.


CONCLUSIONS
The results of this study show that the allergoid SLIT is safe and effective in decreasing symptom scores and drug use in rhinitic patients allergic to grass pollen.
Palma-Carlos
A G
AG
Clinical Allergy Immunology Center, CAIC, Lisbon, Portugal.
Santos
A S
AS
Branco-Ferreira
M
M
Pregal
A L
AL
Palma-Carlos
M L
ML
Bruno
M E
ME
Falagiani
P
P
Riva
G
G
D000286:Administration, Sublingual; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000080384:Allergoids; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D052179:Antigens, Plant / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D003131:Combined Modality Therapy; D003233:Conjunctivitis, Allergic / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000379:methods / Q000706:statistics & numerical data; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009299:Nasal Provocation Tests; D010936:Plant Extracts; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D012621:Seasons
D000305:Adrenal Cortex Hormones; D000080384:Allergoids; D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D052179:Antigens, Plant; D006634:Histamine H1 Antagonists; D010936:Plant Extracts